A French CD­MO looks to add even more cell and gene ther­a­py ca­pac­i­ty at a Paris-area site

French CD­MO Yposke­si will build its sec­ond com­mer­cial cell and gene ther­a­py fa­cil­i­ty in Cor­beil-Es­sonnes, near Paris, the com­pa­ny an­nounced last week.

The project is dubbed SKY, and will al­so de­vel­op a glob­al re­source for drug de­vel­op­ers of ATMPs. It will cost about $71 mil­lion, and en­com­pass 50,000 square feet up­on com­ple­tion. The Project will cre­ate 80 new jobs, and ad­dress a short­age in man­u­fac­tur­ing ca­pac­i­ty for com­pa­nies look­ing to ad­vance clin­i­cal tri­als and com­mer­cial­ize ther­a­peu­tics, the press re­lease said. The site will have two ad­di­tion­al pro­duc­tion lines and sev­er­al 1,000-liter biore­ac­tors.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.